Management of obesity in the psychiatrist's office

World Psychiatry

Volumn 13, Issue 2, 2014, Pages 193-195

  Chwastiak, Lydia ^a   Tek, Cenk ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; ANTIHISTAMINIC AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HYDROXYZINE; LITHIUM; LORCASERIN; METFORMIN; MIRTAZAPINE; OLANZAPINE; PHENTERMINE; QUETIAPINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

BARIATRIC SURGERY; BEHAVIOR CHANGE; BODY MASS; COGNITIVE THERAPY; DISEASE SEVERITY; HUMAN; INCREASED APPETITE; LIFESTYLE MODIFICATION; MENTAL DISEASE; NUTRITIONAL STATUS; OBESITY; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT CONTRAINDICATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84901781656     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20138     Document Type: Review

References (16)

1. Correll CU, Druss BG, Lombardo I, et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 2010; 61: 892-8.
2. Druss BG, Zhao L, Von Esenwein S, et al. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care 2011; 49: 599-604.
3. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
4. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947-56.
5. Foley DL, Morley KI,. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011; 68: 609-16.
6. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
7. Brunner EJ, Rees K, Ward K, et al. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007; 4: CD002128.
8. Ali MK, Echouffo-Tcheugui JB, Williamson DF,. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Affairs 2012; 31: 67-75.
9. Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013; 368: 1594-602.
10. Bartels S, Desilets R,. Health promotion programs for people with serious mental illness (prepared by the Dartmouth Health Promotion Research Team). Washington: SAMHSA-HRSA Center for Integrated Health Solutions, 2012.
11. Yanovski SZ, Yanovski JA,. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74-86.
12. Maayan L, Vakhrusheva J, Correll CU,. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520-30.
13. Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013; 170: 1032-40.
14. Imfeld P, Bodmer M, Jick SS, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc 2012; 60: 916-2 1.
15. Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012; 98: 1763-77.
16. Ahmed AT, Warton EM, Schaefer CA,. The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord 2013; 15: 753-63.